Citations

Clear

3942 citation(s) found for "To, Van".

Insulin’s Effect on Synthesis Rates of Liver Proteins
Ahlman, B., Fu, Aizhong, Berg, C. J. M. G. van den, O’Brien, Peter C. , Charlton, Michael , Nair, K. Sreekumaran

Mayo Clinic

Diabetes | March 6, 2007 | Volume: 50 | Issue: 5 | Pages: 947-954

10.2337/diabetes.50.5.947 | PMID 11334437 Get It

Insulin’s effect on the synthesis of liver proteins remains to be fully defined. Previous studies using various surrogate measures of amino acyl–tRNA have reported variable results of insulin’s effect on liver protein synthesis. We determined the effect of insulin with or without amino acid supplementation on the synthesis rates of liver proteins (tissue, albumin, and fibrinogen) using l-[1-13C]Leu as a tracer in 24 male miniature swine. In addition, we compared the isotopic enrichment of different precursors of liver proteins with that of amino acyl−tRNA using l-[1-13C]Leu and l-[15N]Phe as tracers. Although liver tissue fluid enrichment of [13C]Leu and [15N]Phe and that of plasma [13C]ketoisocaproatic acid (KIC) were very similar to that of tRNA, plasma isotopic enrichment of both Leu and Phe were substantially higher (P < 0.01) and VLDL apolipoprotein-B100 enrichment was lower (P < 0.01) than the respective amino acyl−tRNA enrichment. Plasma KIC enrichment most accurately predicted leucyl-tRNA enrichment, whereas plasma Leu enrichment was best correlated with that of tRNA. Neither insulin alone nor insulin plus amino acid infusion had an effect on liver tissue protein synthesis. In contrast, insulin alone decreased the albumin synthesis rate, and insulin with amino acids maintained the albumin synthesis rate. Insulin with or without amino acids inhibited the fibrinogen synthesis rate. These results, based on synthetic rates using amino acyl–tRNA, were consistent with those obtained using KIC or tissue fluid Leu or Phe as precursor pools. These studies demonstrated that plasma KIC enrichment is a convenient and reliable surrogate measure of leucyl-tRNA in liver. We also concluded that insulin has differential effects on the synthesis rates of liver proteins. Whereas insulin with or without amino acid supplement has no acute effect on the synthesis of liver tissue protein, insulin has a substantial inhibitory effect on fibrinogen synthesis. In contrast, insulin administration along with amino supplement is necessary to maintain albumin synthesis rate.
Prolonged Fasting Hypoglycemia Due to Insulin Antibodies in Patient With Non-Insulin-Dependent Diabetes Mellitus: Effect of Insulin Withdrawal on Insulin-Antibody—Binding Kinetics
Haeften, Timon W. van, Krom, Bethany A, Gerich, John E.

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 10 | Issue: 2 | Pages: 160-163

10.2337/diacare.10.2.160 | PMID 3582076 Get It

Fasting hypoglycemia, which persisted for 3 days after insulin treatment was stopped,occurred in a patient with non-insulin-dependent diabetes mellitus who had inappropriate plasma free-insulin levels (18–25 μU/ml) and extremely high antibody-bound insulin (>20,000 μU/ml) but normal counterregulatory hormone secretion and plasma C-peptide levels. The amount of antibody-bound insulin decreased in a biphasic pattern over13 mo of observation with an initial half-life of 35 days and a more gradual decrease with a half-life of 160 days. The number of high-affinity antibody binding sites was virtually identical to the amount of antibody-bound insulin in the patient's plasma. We conclude that the patient's fasting hyperinsulinemia and hypoglycemia were due to release of antibody-bound insulin.
Percutaneous cholecystostomy: A valuable technique in high-risk patients with presumed acute cholecystitis
Melin, Matthew M , Sarr, Michael G. , Bender, C E, Heerden, Jon A. van

Mayo Clinic

Journal of British Surgery | March 3, 2007 | Volume: 82 | Issue: 9 | Pages: 1274-1277

10.1002/bjs.1800820939 | PMID 7552017 Get It

Abstract Percutaneous cholecystostomy offers a potentially important therapeutic modality for critically ill patients with acute cholecystitis who represent a high risk for general anaesthesia. The aim of the study was to assess experience with percutaneous cholecystostomy in resolving the acute episode of cholecystitis without operative intervention. Twenty-two consecutive patients with a clinical diagnosis of acute cholecystitis underwent the procedure. All were at high risk for general anaesthesia, and all but one developed cholecystitis while hospitalized for another co-morbid condition; 14 were in an intensive care unit. Twenty-one of the 22 patients proved to have acute cholecystitis (11 acalculous, ten cholelithiasis). There were no acute technical complications. Toxaemia resolved in 17 of the 21 patients with acute cholecystitis. Acute cholecystitis failed to resolve in three patients; all died within 48 h from overwhelming generalized sepsis. One patient required emergency cholecystectomy for bile peritonitis when the cholecystostomy catheter became dislodged 24 h after placement. The 60-day mortality rate for the acalculous and calculous patient groups was 55 and 20 per cent, respectively. Only three interval cholecystectomies have been performed at a mean follow-up of 19 months. In conclusion, percutaneous cholecystostomy may be the procedure of choice for the management of acute cholecystitis in the very high-risk critically ill patient. If symptoms fail to resolve quickly, ongoing sepsis, cholangitis or gallbladder necrosis should be suspected.
Radical pancreatoduodenectomy for misdiagnosed pancreatic mass
Smith, C. Daniel , Behrns, K.E. , Heerden, Jonathan A. van, Sarr, M. G.

Mayo Clinic

Journal of British Surgery | March 3, 2007 | Volume: 81 | Issue: 4 | Pages: 585-589

10.1002/bjs.1800810435 | PMID 7911387 Get It

Abstract Occasionally pancreatoduodenectomy is performed for clinically suspected pancreatic malignancy only for the surgeon to find that a benign aetiology accounts for the pancreatic mass. The aim of this study was twofold: to determine the incidence of pancreatoduodenectomy performed for a misdiagnosis of pancreatoduodenal malignancy and to identify potentially avoidable errors in preoperative and intraoperative judgement. Between 1956 and 1990, radical pancreatoduodenectomy was performed in 603 patients at the Mayo Clinic; 29 (5 per cent) underwent pancreatoduodenectomy for a diagnosis made before and during surgery of primary pancreatic or periampullary malignancy that was later proven histopathologically to be either unsuspected subacute or chronic pancreatitis (22 patients), benign fibrous common bile duct stricture (two), and penetrating duodenal ulcer, metastatic melanoma, ampullary adenoma, intrahepatic drug-induced cholestasis and pseudocyst (one each). No patient had a preoperative diagnosis of chronic pancreatitis. Weight loss, pain and/or jaundice were present in 27 of the 29 patients. Objective imaging tests, such as computed tomography, ultrasonography and/or endoscopic retrograde cholangio-pancreatography, were performed in 25 patients. Potential errors in judgement may be avoided by a more aggressive attempt at biopsy in selected patients; in others, resection for presumed malignancy may be unavoidable.
Simultaneous phaeochromocytoma and renal cell carcinoma: Report of a case and review of the literature
Ducatman, Barbara S., Scheithauer, B. W., Heerden, Jon A. van, Sheedy, Patrick F.

Mayo Clinic

Journal of British Surgery | March 2, 2007 | Volume: 70 | Issue: 7 | Pages: 415-418

10.1002/bjs.1800700709 | PMID 6871623 Get It

Adrenalectomy for metastatic disease to the adrenal glands
Lo, Chung Yau, Heerden, Jon A. van, Søreide, Jon Arne , Grant, Clive S., Thompson, Geoffrey B. , Lloyd, Ricardo V., Harmsen, William S.

Mayo Clinic

Journal of British Surgery | March 2, 2007 | Volume: 83 | Issue: 4 | Pages: 528-531

10.1002/bjs.1800830432 | PMID 8665251 Get It

Abstract A policy of supportive treatment is frequently adopted for patients with metastatic disease to the adrenal glands. This study reports an experience with adrenalectomy for adrenal metastasis. Between 1983 and 1993, adrenalectomy was performed in 52 patients for metastasis to the adrenal glands. Survival was calculated by the Kaplan- Meier method and compared with the log rank test. Primary tumour sites included kidney (n = 15), lung (n = 11), colon (n = 7), unknown (n = 5), stomach (n = 3), melanoma (n = 3) and other (n = 8). Adenocarcinoma (69 per cent) was the most common histological cell type. Thirty-two patients were asymptomatic on initial evaluation. Symptomatic adrenal pain relief was achieved in 11 of 13 patients. Overall survival rates were 73 per cent at 1 year and 40 per cent at 2 years. Patients with potentially curative resection had better survival than those who had a palliative procedure. Patients with adrenal metastases due to adenocarcinoma had improved survival compared with that in those with other histological cell types. Although long-term survival is generally poor, highly selected patients with adrenal metastasis (symptomatic disease or adenocarcinoma) may benefit from surgical resection.
A buccal mucosa carcinoma treated with high dose rate brachytherapy
Prisciandaro, Joann I. , Foote, Robert L. , Herman, Michael , Lee, Sally J., LaJoie, Wayne N., Blarcom, Andrew B. Van, Yeakel, Peter D.

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 22, 2007 | Volume: 6 | Issue: 1 | Pages: 8-12

10.1120/jacmp.v6i1.2064 | PMID 15770193 Get It

This manuscript presents a case of early stage squamous cell carcinoma of the left buccal mucosa treated with intensity‐modulated radiation therapy (IMRT) followed by a high‐dose rate (HDR) brachytherapy boost. With limited literature available on HDR mold (stent) radiotherapy for oral cancer, a discussion on the issues encountered during treatment planning and delivery may prove to be insightful for facilities faced with a similar challenge.PACS numbers: 87.53.Jw, 87.53.Tf, 87.59.Ci, 87.59.Fm
Aging-Associated Vascular Phenotype in Mutant Mice With Low Levels of BubR1
Matsumoto, Takuya , Baker, Darren J. , Mozammel, Gazi, Katušić, Zvonimir S. , Deursen, Jan M. van , d’Uscio, Livius V. , Baker, Darren J

Mayo Clinic

Stroke | February 3, 2007 | Volume: 38 | Issue: 3 | Pages: 1050-1056

10.1161/01.str.0000257967.86132.01 | PMID 17272762 Get It

Background and Purpose— Aging is a major risk for stroke and a highly complex biological process believed to involve multiple mechanisms. Mutant mice that express low levels of the spindle assembly checkpoint protein BubR1 are known to develop several aging-associated phenotypes at a very young age, including cataracts, lordokyphosis, loss of subcutaneous fat, and impaired wound healing. However, whether BubR1 acts to prevent vascular aging has not yet been established. The present study was designed to investigate the vascular phenotype of mutant mice with low levels of BubR1. Methods— Morphological, functional, and biochemical analyses were performed on aortas and carotid arteries of 3- to 5-month-old BubR1 mutant mice and wild-type littermates. Results— Arterial wall thickness and inner diameter were significantly reduced in BubR1 mutant mice. Arterial walls of BubR1 mutant mice had low numbers of medial smooth muscle cells. Masson trichrome staining showed profound fibrosis in arterial walls of BubR1 mutant. In agreement with these morphological changes, functional analysis of pressurized isolated carotid arteries of BubR1 mutant mice demonstrated reduced elastic properties. Endothelium-dependent relaxations to acetylcholine and endothelium-independent relaxations to the nitric oxide donor DEA-NONOate were significantly reduced in carotid arteries of BubR1 mutant mice. Furthermore, enzymatic activity of nitric oxide synthase and levels of cyclic GMP were significantly reduced in aortas of mutant mice, but production of superoxide anions was significantly increased. Conclusions— These findings demonstrate that BubR1 insufficiency in mice results in phenotypic changes reminiscent of vascular aging in humans and suggest a role for BubR1 in suppressing the vascular aging process.
Influenza virus targets the mRNA export machinery and the nuclear pore complex
Satterly, Neal, Tsai, Pei-Ling, Deursen, Jan van, Nussenzveig, Daniel R., Waziry, Paula A. Faria , Levay, Agata , Levy, David E. , Fontoura, Beatriz M. A. , Wang, Yaming

Mayo Clinic

Proceedings of the National Academy of Sciences | February 2, 2007 | Volume: 104 | Issue: 6 | Pages: 1853-1858

10.1073/pnas.0610977104 | PMID 17267598 Get It

The NS1 protein of influenza A virus is a major virulence factor that is essential for pathogenesis. NS1 functions to impair innate and adaptive immunity by inhibiting host signal transduction and gene expression, but its mechanisms of action remain to be fully elucidated. We show here that NS1 forms an inhibitory complex with NXF1/TAP, p15/NXT, Rae1/mrnp41, and E1B-AP5, which are key constituents of the mRNA export machinery that interact with both mRNAs and nucleoporins to direct mRNAs through the nuclear pore complex. Increased levels of NXF1, p15, or Rae1 revert the mRNA export blockage induced by NS1. Furthermore, influenza virus down-regulates Nup98, a nucleoporin that is a docking site for mRNA export factors. Reduced expression of these mRNA export factors renders cells highly permissive to influenza virus replication, demonstrating that proper levels of key constituents of the mRNA export machinery protect against influenza virus replication. Because Nup98 and Rae1 are induced by interferons, down-regulation of this pathway is likely a viral strategy to promote viral replication. These findings demonstrate previously undescribed influenza-mediated viral–host interactions and provide insights into potential molecular therapies that may interfere with influenza infection.
The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Goldberg, Richard M. , Rothenberg, Mace L., Benson, Al B. , Blanke, Charles D. , Diasio, Robert B. , Grothey, Axel, Lenz, Heinz‐Josef , Meropol, Neal J. , Ramanathan, Ramesh K., Becerra, Carlos H.R., Wickham, Rita , Armstrong, Delma, Viele, Carol, Cutsem, Eric Van

Mayo Clinic

The Oncologist | January 17, 2007 | Volume: 12 | Issue: 1 | Pages: 38-50

10.1634/theoncologist.12-1-38 | PMID 17227899 Get It

Learning ObjectivesAfter completing this course, the reader should be able to: Discuss recent progress in the treatment of patients with advanced colorectal cancer.Define the continuum-of-care approach and how it may differ from our current approach to the treatment of patients with advanced colorectal cancer.Identify key factors in treatment selection for patients with advanced colorectal cancer.Explain the impact of each active drug in the treatment of advanced colorectal cancer and the impact of treatment with multiple agents over the course of the disease.CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com